New triple combination therapies, combining two different correctors with VX-770 further broadened the reach of modulator treatment, with recent demonstration of clinical benefits for patients carrying at least one copy of F508del-CFTR (covering ∼90% of the CF population currently in the CFTR2 database, RRID:SCR_019078) (16, 17). Here, CFTR is linked to cystic fibrosis.